Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Department of Neurology, St, Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
JAMA Neurol. 2019 Jul 1;76(7):841-849. doi: 10.1001/jamaneurol.2019.0905.
Reliable biomarkers associated with disability worsening in multiple sclerosis (MS) are still needed.
To determine a possible association of intrathecal IgG synthesis and early disability worsening as measured by Expanded Disability Status Scale (EDSS) scoring in patients with relapsing-remitting MS or clinically isolated syndrome.
DESIGN, SETTING, AND PARTICIPANTS: Cerebrospinal fluid measurements and clinical data from the observational longitudinal German national multiple sclerosis cohort were analyzed. Patients were recruited between August 2010 and November 2015 from 18 centers. Data analysis was completed from August 2018 to December 2018.
Patients were offered standard immunotherapies per national treatment guidelines.
A possible association between intrathecal IgG synthesis and risk of EDSS worsening 4 years after study inclusion was tested as the primary end point by multivariable binomial regression analysis. Kaplan-Meier analysis with a log-rank test was used to assess the association of intrathecal IgG synthesis with the time to EDSS worsening. Associations between intrathecal IgM or IgA synthesis and other cerebrospinal fluid parameters and EDSS worsening were analyzed as exploratory end points. Data collection began before the hypotheses were formulated.
Of all 1376 patients in the German Competence Network of Multiple Sclerosis cohort, 703 patients were excluded owing to missing cerebrospinal fluid or EDSS data. Of the 673 included patients, 459 (68.2%) were women. The mean (SD) age at baseline was 34 (10) years. Intrathecal IgG synthesis was associated with a higher risk of EDSS worsening after 4 years (odds ratio, 2.02 [95% CI, 1.15-3.58]; P = .01), independent of the occurrence of relapses and disease-modifying therapy. Additionally, intrathecal IgG synthesis was associated with earlier EDSS worsening; 4 years after study entry, worsening occurred in 28.4% (95% CI, 22.7%-34.1%) and 18.1% (95% CI, 12.4%-23.9%) of patients with and without intrathecal IgG synthesis, respectively. No association of other routine cerebrospinal fluid parameters with EDSS worsening was found.
Patients with new diagnoses of relapsing-remitting multiple sclerosis or clinically isolated syndrome with intrathecal IgG synthesis had a higher risk of and shorter time to EDSS worsening across a 4-year period of follow-up. Intrathecal IgG synthesis is a potentially useful marker for disability worsening in patients with multiple sclerosis and may be useful for early treatment decisions.
仍需要与多发性硬化症(MS)残疾恶化相关的可靠生物标志物。
确定在复发缓解型多发性硬化症或临床孤立综合征患者中,鞘内 IgG 合成与扩展残疾状况量表(EDSS)评分所测早期残疾恶化之间是否存在关联。
设计、地点和参与者:对观察性纵向德国国家多发性硬化症队列的脑脊液测量和临床数据进行了分析。患者于 2010 年 8 月至 2015 年 11 月期间在 18 个中心招募。数据分析于 2018 年 8 月至 2018 年 12 月完成。
根据国家治疗指南,为患者提供了标准免疫治疗。
通过多变量二项式回归分析,将 4 年后 EDSS 恶化的风险作为主要终点,对鞘内 IgG 合成与风险之间的可能关联进行了测试。使用对数秩检验的 Kaplan-Meier 分析评估了鞘内 IgG 合成与 EDSS 恶化之间的时间关联。对鞘内 IgM 或 IgA 合成与其他脑脊液参数和 EDSS 恶化之间的关联进行了分析,作为探索性终点。数据收集在提出假设之前开始。
在德国多发性硬化症网络协作组的 1376 名患者中,由于缺少脑脊液或 EDSS 数据,703 名患者被排除在外。在纳入的 673 名患者中,459 名(68.2%)为女性。基线时的平均(SD)年龄为 34(10)岁。鞘内 IgG 合成与 4 年后 EDSS 恶化风险升高相关(比值比,2.02[95%CI,1.15-3.58];P = .01),与复发和疾病修正治疗无关。此外,鞘内 IgG 合成与 EDSS 恶化的发生时间更早相关;在研究入组后 4 年,有和没有鞘内 IgG 合成的患者中分别有 28.4%(95%CI,22.7%-34.1%)和 18.1%(95%CI,12.4%-23.9%)的患者出现 EDSS 恶化。未发现其他常规脑脊液参数与 EDSS 恶化有关。
在新发复发缓解型多发性硬化症或临床孤立综合征患者中,有鞘内 IgG 合成的患者在 4 年的随访中,EDSS 恶化的风险更高,出现 EDSS 恶化的时间更早。鞘内 IgG 合成是多发性硬化症患者残疾恶化的一个潜在有用标志物,可能有助于早期治疗决策。